Effects of Pomegranate Extract Supplementation on Cardiovascular Risk Factors and Physical Function in Hemodialysis Patients

Pei Tzu Wu, Peter J. Fitschen, Brandon M. Kistler, Jin Hee Jeong, Hae Ryong Chung, Michael Aviram, Shane Phillips, Bo Fernhall, Kenneth R. Wilund

Research output: Contribution to journalArticle

  • 15 Citations

Abstract

The purpose of this study was to evaluate the effects of oral supplementation with pomegranate extract on cardiovascular risk, physical function, oxidative stress, and inflammation in hemodialysis (HD) patients. Thirty-three HD subjects were randomized to the pomegranate (POM) or placebo (CON) group. Patients in POM ingested a 1000 mg capsule of a purified pomegranate polyphenol extract 7 days/week for 6 months. Individuals in CON ingested a noncaloric placebo capsule using the same protocol. Measurements were conducted at baseline and repeated 6 months following the start of the intervention. Brachial blood pressure (BP) was obtained using an automatic digital BP monitor. Cardiovascular risk was assessed using ultrasound and arterial tonometry. Blood samples were collected for the measurements of circulating markers of inflammation, oxidative stress, and antioxidant capacity. Muscle strength and physical function were assessed by isokinetic dynamometry, a validated shuttle walk test, and a battery of tests to assess functional fitness. Systolic blood pressure and diastolic blood pressure were reduced by 24±13.7 and 10±5.3 mmHg, respectively, in POM (P<.05). However, the BP differences in POM were no longer significant after controlling for baseline BP. The paraoxonase-1 activity increased by 26.6% (P<.05) in POM, compared to no significant change in CON. However, pomegranate supplementation had no effect on other markers of cardiovascular disease risk, inflammation and oxidative stress, or measures of physical function and muscle strength. While pomegranate extract supplementation may reduce BP and increase the antioxidant activity in HD patients, it does not improve other markers of cardiovascular risk, physical function, or muscle strength.

LanguageEnglish (US)
Pages941-949
Number of pages9
JournalJournal of Medicinal Food
Volume18
Issue number9
DOIs
StatePublished - Sep 1 2015

Fingerprint

Punicaceae
Renal Dialysis
Blood Pressure
Muscle Strength
Oxidative Stress
Inflammation
Capsules
Antioxidants
Placebos
Blood Pressure Monitors
Aryldialkylphosphatase
Manometry
Polyphenols
Arm
Cardiovascular Diseases

Keywords

  • antioxidant supplementation
  • cardiovascular disease
  • chronic kidney disease
  • oxidative stress
  • physical function

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

Wu, P. T., Fitschen, P. J., Kistler, B. M., Jeong, J. H., Chung, H. R., Aviram, M., ... Wilund, K. R. (2015). Effects of Pomegranate Extract Supplementation on Cardiovascular Risk Factors and Physical Function in Hemodialysis Patients. Journal of Medicinal Food, 18(9), 941-949. https://doi.org/10.1089/jmf.2014.0103

Effects of Pomegranate Extract Supplementation on Cardiovascular Risk Factors and Physical Function in Hemodialysis Patients. / Wu, Pei Tzu; Fitschen, Peter J.; Kistler, Brandon M.; Jeong, Jin Hee; Chung, Hae Ryong; Aviram, Michael; Phillips, Shane; Fernhall, Bo; Wilund, Kenneth R.

In: Journal of Medicinal Food, Vol. 18, No. 9, 01.09.2015, p. 941-949.

Research output: Contribution to journalArticle

Wu, Pei Tzu ; Fitschen, Peter J. ; Kistler, Brandon M. ; Jeong, Jin Hee ; Chung, Hae Ryong ; Aviram, Michael ; Phillips, Shane ; Fernhall, Bo ; Wilund, Kenneth R. / Effects of Pomegranate Extract Supplementation on Cardiovascular Risk Factors and Physical Function in Hemodialysis Patients. In: Journal of Medicinal Food. 2015 ; Vol. 18, No. 9. pp. 941-949.
@article{551dc3621d2f482b89e5c8ac6cd0823b,
title = "Effects of Pomegranate Extract Supplementation on Cardiovascular Risk Factors and Physical Function in Hemodialysis Patients",
abstract = "The purpose of this study was to evaluate the effects of oral supplementation with pomegranate extract on cardiovascular risk, physical function, oxidative stress, and inflammation in hemodialysis (HD) patients. Thirty-three HD subjects were randomized to the pomegranate (POM) or placebo (CON) group. Patients in POM ingested a 1000 mg capsule of a purified pomegranate polyphenol extract 7 days/week for 6 months. Individuals in CON ingested a noncaloric placebo capsule using the same protocol. Measurements were conducted at baseline and repeated 6 months following the start of the intervention. Brachial blood pressure (BP) was obtained using an automatic digital BP monitor. Cardiovascular risk was assessed using ultrasound and arterial tonometry. Blood samples were collected for the measurements of circulating markers of inflammation, oxidative stress, and antioxidant capacity. Muscle strength and physical function were assessed by isokinetic dynamometry, a validated shuttle walk test, and a battery of tests to assess functional fitness. Systolic blood pressure and diastolic blood pressure were reduced by 24±13.7 and 10±5.3 mmHg, respectively, in POM (P<.05). However, the BP differences in POM were no longer significant after controlling for baseline BP. The paraoxonase-1 activity increased by 26.6{\%} (P<.05) in POM, compared to no significant change in CON. However, pomegranate supplementation had no effect on other markers of cardiovascular disease risk, inflammation and oxidative stress, or measures of physical function and muscle strength. While pomegranate extract supplementation may reduce BP and increase the antioxidant activity in HD patients, it does not improve other markers of cardiovascular risk, physical function, or muscle strength.",
keywords = "antioxidant supplementation, cardiovascular disease, chronic kidney disease, oxidative stress, physical function",
author = "Wu, {Pei Tzu} and Fitschen, {Peter J.} and Kistler, {Brandon M.} and Jeong, {Jin Hee} and Chung, {Hae Ryong} and Michael Aviram and Shane Phillips and Bo Fernhall and Wilund, {Kenneth R.}",
year = "2015",
month = "9",
day = "1",
doi = "10.1089/jmf.2014.0103",
language = "English (US)",
volume = "18",
pages = "941--949",
journal = "Journal of Medicinal Food",
issn = "1096-620X",
publisher = "Mary Ann Liebert Inc.",
number = "9",

}

TY - JOUR

T1 - Effects of Pomegranate Extract Supplementation on Cardiovascular Risk Factors and Physical Function in Hemodialysis Patients

AU - Wu, Pei Tzu

AU - Fitschen, Peter J.

AU - Kistler, Brandon M.

AU - Jeong, Jin Hee

AU - Chung, Hae Ryong

AU - Aviram, Michael

AU - Phillips, Shane

AU - Fernhall, Bo

AU - Wilund, Kenneth R.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - The purpose of this study was to evaluate the effects of oral supplementation with pomegranate extract on cardiovascular risk, physical function, oxidative stress, and inflammation in hemodialysis (HD) patients. Thirty-three HD subjects were randomized to the pomegranate (POM) or placebo (CON) group. Patients in POM ingested a 1000 mg capsule of a purified pomegranate polyphenol extract 7 days/week for 6 months. Individuals in CON ingested a noncaloric placebo capsule using the same protocol. Measurements were conducted at baseline and repeated 6 months following the start of the intervention. Brachial blood pressure (BP) was obtained using an automatic digital BP monitor. Cardiovascular risk was assessed using ultrasound and arterial tonometry. Blood samples were collected for the measurements of circulating markers of inflammation, oxidative stress, and antioxidant capacity. Muscle strength and physical function were assessed by isokinetic dynamometry, a validated shuttle walk test, and a battery of tests to assess functional fitness. Systolic blood pressure and diastolic blood pressure were reduced by 24±13.7 and 10±5.3 mmHg, respectively, in POM (P<.05). However, the BP differences in POM were no longer significant after controlling for baseline BP. The paraoxonase-1 activity increased by 26.6% (P<.05) in POM, compared to no significant change in CON. However, pomegranate supplementation had no effect on other markers of cardiovascular disease risk, inflammation and oxidative stress, or measures of physical function and muscle strength. While pomegranate extract supplementation may reduce BP and increase the antioxidant activity in HD patients, it does not improve other markers of cardiovascular risk, physical function, or muscle strength.

AB - The purpose of this study was to evaluate the effects of oral supplementation with pomegranate extract on cardiovascular risk, physical function, oxidative stress, and inflammation in hemodialysis (HD) patients. Thirty-three HD subjects were randomized to the pomegranate (POM) or placebo (CON) group. Patients in POM ingested a 1000 mg capsule of a purified pomegranate polyphenol extract 7 days/week for 6 months. Individuals in CON ingested a noncaloric placebo capsule using the same protocol. Measurements were conducted at baseline and repeated 6 months following the start of the intervention. Brachial blood pressure (BP) was obtained using an automatic digital BP monitor. Cardiovascular risk was assessed using ultrasound and arterial tonometry. Blood samples were collected for the measurements of circulating markers of inflammation, oxidative stress, and antioxidant capacity. Muscle strength and physical function were assessed by isokinetic dynamometry, a validated shuttle walk test, and a battery of tests to assess functional fitness. Systolic blood pressure and diastolic blood pressure were reduced by 24±13.7 and 10±5.3 mmHg, respectively, in POM (P<.05). However, the BP differences in POM were no longer significant after controlling for baseline BP. The paraoxonase-1 activity increased by 26.6% (P<.05) in POM, compared to no significant change in CON. However, pomegranate supplementation had no effect on other markers of cardiovascular disease risk, inflammation and oxidative stress, or measures of physical function and muscle strength. While pomegranate extract supplementation may reduce BP and increase the antioxidant activity in HD patients, it does not improve other markers of cardiovascular risk, physical function, or muscle strength.

KW - antioxidant supplementation

KW - cardiovascular disease

KW - chronic kidney disease

KW - oxidative stress

KW - physical function

UR - http://www.scopus.com/inward/record.url?scp=84941339418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941339418&partnerID=8YFLogxK

U2 - 10.1089/jmf.2014.0103

DO - 10.1089/jmf.2014.0103

M3 - Article

VL - 18

SP - 941

EP - 949

JO - Journal of Medicinal Food

T2 - Journal of Medicinal Food

JF - Journal of Medicinal Food

SN - 1096-620X

IS - 9

ER -